• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
NRAS tumor mutations are associated with reduced odds of dermatologic adverse events in patients with metastatic melanoma receiving immune checkpoint inhibitors.NRAS肿瘤突变与接受免疫检查点抑制剂治疗的转移性黑色素瘤患者发生皮肤不良事件的几率降低相关。
JAAD Int. 2024 Nov 28;18:165-167. doi: 10.1016/j.jdin.2024.11.004. eCollection 2025 Feb.
2
Analysis on the risk of myasthenia gravis related to immune checkpoint inhibitors based on the US FDA Adverse Event Reporting System.基于美国 FDA 不良事件报告系统的免疫检查点抑制剂相关重症肌无力风险分析。
Cancer Med. 2023 Oct;12(19):19491-19499. doi: 10.1002/cam4.6559. Epub 2023 Sep 19.
3
Severe immune-related adverse events of immune checkpoint inhibitors for advanced non-small cell lung cancer: a network meta-analysis of randomized clinical trials.免疫检查点抑制剂治疗晚期非小细胞肺癌的严重免疫相关不良事件：一项随机临床试验的网络荟萃分析。
Cancer Immunol Immunother. 2022 Sep;71(9):2239-2254. doi: 10.1007/s00262-022-03140-5. Epub 2022 Feb 6.
4
Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Advanced Non-small Cell Lung Cancer: A Network Meta-Analysis of Randomized Clinical Trials.与免疫检查点抑制剂治疗晚期非小细胞肺癌相关的免疫相关不良事件：一项随机临床试验的网络荟萃分析
Front Pharmacol. 2021 Oct 25;12:686876. doi: 10.3389/fphar.2021.686876. eCollection 2021.
5
Neuro-Ophthalmic Complications in Patients Treated With CTLA-4 and PD-1/PD-L1 Checkpoint Blockade.接受 CTLA-4 和 PD-1/PD-L1 检查点阻断治疗的患者的神经眼科并发症。
J Neuroophthalmol. 2021 Dec 1;41(4):519-530. doi: 10.1097/WNO.0000000000001148.
6
Meta-analysis of immune-related adverse events of immune checkpoint inhibitor therapy in cancer patients.癌症患者免疫检查点抑制剂治疗相关免疫不良反应的荟萃分析。
Thorac Cancer. 2020 Sep;11(9):2406-2430. doi: 10.1111/1759-7714.13541. Epub 2020 Jul 8.
7
Pharmacovigilance study on the reporting frequency of atrial fibrillation with immune checkpoint inhibitors: insights from FDA Adverse Event Reporting System.免疫检查点抑制剂所致心房颤动报告频率的药物警戒研究：来自美国食品药品监督管理局不良事件报告系统的见解
Ther Adv Drug Saf. 2025 Apr 21;16:20420986241312497. doi: 10.1177/20420986241312497. eCollection 2025.
8
Comprehensive Evaluation of Anti-PD-1, Anti-PD-L1, Anti-CTLA-4 and Their Combined Immunotherapy in Clinical Trials: A Systematic Review and Meta-analysis.临床试验中抗PD-1、抗PD-L1、抗CTLA-4及其联合免疫疗法的综合评价：一项系统评价与Meta分析
Front Pharmacol. 2022 May 25;13:883655. doi: 10.3389/fphar.2022.883655. eCollection 2022.
9
Immune-related adverse events associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system.免疫检查点抑制剂相关的免疫相关不良事件：FDA 不良事件报告系统的更新综合比例失调分析。
Int Immunopharmacol. 2021 Jun;95:107498. doi: 10.1016/j.intimp.2021.107498. Epub 2021 Mar 13.
10
Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence.根据美国国立综合癌症网络（NCCN）指南及证据水平对美国食品药品监督管理局（FDA）批准的免疫检查点抑制剂适应症的综述。
Cancers (Basel). 2020 Mar 20;12(3):738. doi: 10.3390/cancers12030738.

本文引用的文献

1
Sex Differences in Risk of Severe Adverse Events in Patients Receiving Immunotherapy, Targeted Therapy, or Chemotherapy in Cancer Clinical Trials.癌症临床试验中接受免疫治疗、靶向治疗或化疗的患者发生严重不良事件的风险的性别差异。
J Clin Oncol. 2022 May 1;40(13):1474-1486. doi: 10.1200/JCO.21.02377. Epub 2022 Feb 4.
2
Association of NRAS Mutation With Clinical Outcomes of Anti-PD-1 Monotherapy in Advanced Melanoma: A Pooled Analysis of Four Asian Clinical Trials.NRAS 突变与抗 PD-1 单药治疗晚期黑色素瘤的临床结局的关联：四项亚洲临床试验的汇总分析。
Front Immunol. 2021 Jul 5;12:691032. doi: 10.3389/fimmu.2021.691032. eCollection 2021.
3
Association of Immune Related Adverse Events With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Cancers: A Systemic Review and Meta-analysis.免疫相关不良事件与免疫检查点抑制剂疗效及癌症总生存期的关联：一项系统评价和荟萃分析
Front Oncol. 2021 Apr 12;11:633032. doi: 10.3389/fonc.2021.633032. eCollection 2021.
4
Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune-checkpoint inhibitors: A United States population-level analysis.免疫检查点抑制剂治疗患者皮肤毒性的发生的流行病学和危险因素：美国人群水平分析。
J Am Acad Dermatol. 2022 Mar;86(3):563-572. doi: 10.1016/j.jaad.2021.03.094. Epub 2021 Apr 2.
5
Validation of OncoPanel: A Targeted Next-Generation Sequencing Assay for the Detection of Somatic Variants in Cancer.OncoPanel验证：一种用于检测癌症体细胞变异的靶向新一代测序分析方法
Arch Pathol Lab Med. 2017 Jun;141(6):751-758. doi: 10.5858/arpa.2016-0527-OA. Epub 2017 Mar 3.

NRAS tumor mutations are associated with reduced odds of dermatologic adverse events in patients with metastatic melanoma receiving immune checkpoint inhibitors.

作者信息

Chang Michael S, Said Jordan T, Akama-Garren Elliot H, Trepanowski Nicole, Bui Ai-Tram N, Giobbie-Hurder Anita, LeBoeuf Nicole R, Hartman Rebecca I

机构信息

Harvard Medical School, Boston, Massachusetts.

Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts.

出版信息

JAAD Int. 2024 Nov 28;18:165-167. doi: 10.1016/j.jdin.2024.11.004. eCollection 2025 Feb.

DOI:10.1016/j.jdin.2024.11.004
PMID:39830992
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11742302/
Abstract
摘要